MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma

Malignant mesothelioma in situ

(2018) Andrew Churg et al.   HISTOPATHOLOGY

Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas

(2018) Kyra B. Berg et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes

(2018) Andrew Churg et al.   LUNG CANCER

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritic

(2018) Yoshiaki Kinoshita et al.   LUNG CANCER

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

(2017) Noémie Leblay et al.   Journal of Thoracic Oncology

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

(2017) Tomoyuki Hida et al.   LUNG CANCER

What is your diagnosis? Bicavitary effusion in a horse

(2017) Jill T. Schappa et al.   VETERINARY CLINICAL PATHOLOGY

Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens

(2016) Harry C. Hwang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma

(2016) Juliana Andrici et al.   HUMAN PATHOLOGY

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

(2016) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Loss of expression of BAP1 is very rare in non-small cell lung carcinoma

(2016) Juliana Andrici et al.   PATHOLOGY

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

(2016) Michele Carbone et al.   Oncotarget

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

(2016) Katya Marjon et al.   Cell Reports

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival

(2016) Jennifer Beebe-Dimmer et al.   Clinical Epidemiology

BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations

(2015) Brandon S. Sheffield et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The evolving role of effusion cytology in the diagnosis of malignant mesothelioma

(2015) A. Paintal   CYTOPATHOLOGY

BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma

(2015) Stephanie M. McGregor et al.   HUMAN PATHOLOGY

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations

(2015) Marta Cigognetti et al.   MODERN PATHOLOGY

The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas

(2012) Zarah Glad Zimling et al.   HISTOPATHOLOGY

CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival

(2010) Alyssa M Krasinskas et al.   MODERN PATHOLOGY